Adjuvant Immunotherapy Approved for Lung Cancer

2022年2月23日 — Adjuvant platinum-based chemotherapy has been the standard-of-care treatment for resected stage IB to III lung cancer with a modest survival ...

由 WF Tang 著作 · 2023 · 被引用 8 次 — Currently, chemotherapy is the standard adjuvant treatment for early-stage non-small cell lung cancer (NSCLC). However, adjuvant cisplatin-based ...

由 ÁA Cortés 著作 · 2015 · 被引用 161 次 — Abstract: Adjuvant chemotherapy (AC) plays now a significant role in the treatment of resected non-small cell lung cancer (NSCLC) patients and has become ...

2004 · 被引用 2983 次 — Conclusions. Cisplatin-based adjuvant chemotherapy improves survival among patients with completely resected non–small-cell lung cancer.

2021年10月26日 — Adjuvant treatments may include chemotherapy, radiation therapy, hormone therapy, and targeted therapy. Many patients with early-stage NSCLC, ...

2024年2月5日 — ... lung cancerAdjuvant chemotherapy trials for non-small cell lung cancer · T, N, and M descriptors for the eighth edition of TNM classification ...

由 JU Lim 著作 · 2022 · 被引用 12 次 — Long‐term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin‐based chemotherapy in resected lung cancer.

由 R Pirker 著作 · 2012 · 被引用 11 次 — Adjuvant chemotherapy improves outcome in patients with completely resected NSCLC as demonstrated in several trials and the LACE meta-analysis. In the positive ...